TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial
Brief Summary: In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced by non- anthracyclines plus cyclophosphamide (AC) based moderately emetogenic chemotherapy (MEC).


Options:
A: Arm Label: APF530 500 mg SC; Type: EXPERIMENTAL; Interventions: Drug: APF530, Drug: Ondansetron placebo, Drug: Fosaprepitant, Drug: Dexamethasone | Arm Label: ondansetron 0.15 mg/kg IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ondansetron, Drug: APF530 placebo, Drug: Fosaprepitant, Drug: Dexamethasone | Intervention Type: DRUG; Name: APF530; Assigned to Arm(s): APF530 500 mg SC | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): ondansetron 0.15 mg/kg IV | Intervention Type: DRUG; Name: Ondansetron placebo; Assigned to Arm(s): APF530 500 mg SC | Intervention Type: DRUG; Name: APF530 placebo; Assigned to Arm(s): ondansetron 0.15 mg/kg IV | Intervention Type: DRUG; Name: Fosaprepitant; Assigned to Arm(s): APF530 500 mg SC, ondansetron 0.15 mg/kg IV | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): APF530 500 mg SC, ondansetron 0.15 mg/kg IV
B: Arm Label: Placebo + Granisetron + Dexamethasone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Granisetron, Drug: Dexamethasone, Drug: Placebo | Arm Label: Rolapitant; Type: EXPERIMENTAL; Interventions: Drug: Rolapitant, Drug: Granisetron, Drug: Dexamethasone | Intervention Type: DRUG; Name: Rolapitant; Assigned to Arm(s): Rolapitant | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone
C: Arm Label: Standard therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Aprepitant / Fosaprepitant therapy; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant / Fosaprepitant | Intervention Type: DRUG; Name: Aprepitant / Fosaprepitant; Assigned to Arm(s): Aprepitant / Fosaprepitant therapy
D: Arm Label: metoclopramide; Type: ACTIVE_COMPARATOR; Interventions: Drug: metoclopramide | Arm Label: dexamethason; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethason | Arm Label: palonosetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: palonosetron | Intervention Type: DRUG; Name: metoclopramide; Assigned to Arm(s): metoclopramide | Intervention Type: DRUG; Name: dexamethason; Assigned to Arm(s): dexamethason | Intervention Type: DRUG; Name: palonosetron; Assigned to Arm(s): palonosetron

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions and Emergency Department Visits: a Randomized, Controlled Trial.
Brief Summary: Hospital readmissions for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) pose burdens to the healthcare system and patients. The aim of this study was to determine whether a screening and educational tool, administered prior to discharge, would result in a decrease in the rate of hospital readmissions.


Options:
A: Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Device: Electrostimulation | Arm Label: Sham ES; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham stimulation | Intervention Type: DEVICE; Name: Electrostimulation; Assigned to Arm(s): ES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): Sham ES
B: Arm Label: Case Management and Self-Management Education; Type: EXPERIMENTAL; Interventions: Other: Case Management and Self-Management Education | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Case Management and Self-Management Education | Intervention Type: OTHER; Name: Case Management and Self-Management Education; Assigned to Arm(s): Case Management and Self-Management Education, Usual Care
C: Arm Label: CHF patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: COPD patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: CHF patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPD patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR-Enhanced Care; Assigned to Arm(s): CHF patients, IVR-Enhanced Care, COPD patients, IVR-Enhanced Care
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Bundle; Type: EXPERIMENTAL; Interventions: Behavioral: Bundle tool | Intervention Type: BEHAVIORAL; Name: Bundle tool; Assigned to Arm(s): Bundle

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions and Emergency Department Visits: a Randomized, Controlled Trial.
Brief Summary: Hospital readmissions for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) pose burdens to the healthcare system and patients. The aim of this study was to determine whether a screening and educational tool, administered prior to discharge, would result in a decrease in the rate of hospital readmissions.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Bundle; Type: EXPERIMENTAL; Interventions: Behavioral: Bundle tool | Intervention Type: BEHAVIORAL; Name: Bundle tool; Assigned to Arm(s): Bundle
B: Arm Label: Spirometry and a brief advice to quit smoking; Type: EXPERIMENTAL; Interventions: Behavioral: Spirometry and a brief advice to quit smoking | Arm Label: Brief advice to quit smoking; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief advice to quit smoking | Intervention Type: BEHAVIORAL; Name: Spirometry and a brief advice to quit smoking; Assigned to Arm(s): Spirometry and a brief advice to quit smoking | Intervention Type: BEHAVIORAL; Name: Brief advice to quit smoking; Assigned to Arm(s): Brief advice to quit smoking
C: Arm Label: Champix plus counselling; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: counselling alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counselling alone | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix plus counselling | Intervention Type: BEHAVIORAL; Name: Counselling alone; Assigned to Arm(s): counselling alone
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Family-supported | Arm Label: Arm 2; Type: OTHER; Interventions: Behavioral: Standard Telephone counseling | Intervention Type: BEHAVIORAL; Name: Family-supported; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Standard Telephone counseling; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions and Emergency Department Visits: a Randomized, Controlled Trial.
Brief Summary: Hospital readmissions for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) pose burdens to the healthcare system and patients. The aim of this study was to determine whether a screening and educational tool, administered prior to discharge, would result in a decrease in the rate of hospital readmissions.


Options:
A: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: COPD evidence based care pathway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COPD evidence based care pathway; Assigned to Arm(s): Pathway
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Bundle; Type: EXPERIMENTAL; Interventions: Behavioral: Bundle tool | Intervention Type: BEHAVIORAL; Name: Bundle tool; Assigned to Arm(s): Bundle
C: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: care at initiative of the patient (usual GP care) | Arm Label: monitoring controls; Type: EXPERIMENTAL; Interventions: Behavioral: regular practice nurse review (monitoring controls) | Arm Label: self-management; Type: EXPERIMENTAL; Interventions: Behavioral: an integrated self-management education program | Intervention Type: BEHAVIORAL; Name: an integrated self-management education program; Assigned to Arm(s): self-management | Intervention Type: BEHAVIORAL; Name: regular practice nurse review (monitoring controls); Assigned to Arm(s): monitoring controls | Intervention Type: BEHAVIORAL; Name: care at initiative of the patient (usual GP care); Assigned to Arm(s): usual care
D: Arm Label: 1 Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action plan | Intervention Type: BEHAVIORAL; Name: Action plan; Assigned to Arm(s): 2 Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preparing to Run Effective Prevention
Brief Summary: Young people can engage in a variety of negative behaviors-such as drug use, underage drinking, and premarital sex-that exact a high toll on local communities. These activities are often the target of community-based prevention efforts. Getting To Outcomes (GTO) is an approach that includes a toolkit, technical assistance, and training, organized around a 10-step process, that helps communities plan, implement, and evaluate the impact of their programs that attempt to prevent these negative behaviors. This study will examine the degree to which Getting To Outcomes helps Boys and Girls Clubs implement an evidence based drug prevention program.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Online Game | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: LGBTQ Resources | Intervention Type: BEHAVIORAL; Name: Online Game; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: LGBTQ Resources; Assigned to Arm(s): Control Group
B: Arm Label: The Real Cost vaping prevention ads - Health effects theme; Type: EXPERIMENTAL; Interventions: Behavioral: The FDA's The REal Cost vaping prevention ads - Health harms theme | Arm Label: The Real Cost vaping prevention ads - Addiction theme; Type: EXPERIMENTAL; Interventions: Behavioral: The FDA's The Real Cost vaping prevention ads - Addiction theme | Arm Label: Neutral vaping ads; Type: OTHER; Interventions: Behavioral: Neutral vaping ads | Intervention Type: BEHAVIORAL; Name: The FDA's The REal Cost vaping prevention ads - Health harms theme; Assigned to Arm(s): The Real Cost vaping prevention ads - Health effects theme | Intervention Type: BEHAVIORAL; Name: The FDA's The Real Cost vaping prevention ads - Addiction theme; Assigned to Arm(s): The Real Cost vaping prevention ads - Addiction theme | Intervention Type: BEHAVIORAL; Name: Neutral vaping ads; Assigned to Arm(s): Neutral vaping ads
C: Arm Label: Vaping Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Social Media Intervention | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Social Media Intervention; Assigned to Arm(s): Vaping Intervention
D: Arm Label: Project CHOICE + Getting To Outcomes; Type: EXPERIMENTAL; Interventions: Behavioral: Getting To Outcomes, Behavioral: Project CHOICE | Arm Label: Project CHOICE only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Project CHOICE | Intervention Type: BEHAVIORAL; Name: Getting To Outcomes; Assigned to Arm(s): Project CHOICE + Getting To Outcomes | Intervention Type: BEHAVIORAL; Name: Project CHOICE; Assigned to Arm(s): Project CHOICE + Getting To Outcomes, Project CHOICE only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-based Medication Adherence Program for Nicotine Dependence Treatment
Brief Summary: The purpose of this pilot study is to evaluate the acceptability and feasibility of the proposed smoking cessation intervention (called MyMAP or My Mobile Advice Program).


Options:
A: Arm Label: mHealth self-help + varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Cognitive-behavioral self-help | Arm Label: mHealth MyMAP program + varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Cognitive-behavioral self-help, Behavioral: MyMAP (My Mobile Advice Program) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): mHealth MyMAP program + varenicline, mHealth self-help + varenicline | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral self-help; Assigned to Arm(s): mHealth MyMAP program + varenicline, mHealth self-help + varenicline | Intervention Type: BEHAVIORAL; Name: MyMAP (My Mobile Advice Program); Assigned to Arm(s): mHealth MyMAP program + varenicline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Smoking Cessation Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone Quitline Smoking Cessation Program | Intervention Type: BEHAVIORAL; Name: Telemedicine Smoking Cessation Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Telephone Quitline Smoking Cessation Program; Assigned to Arm(s): 2
C: Arm Label: electronic mail; Type: EXPERIMENTAL; Interventions: Other: electronic mail | Arm Label: brief advise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: electronic mail; Assigned to Arm(s): electronic mail
D: Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Web-based smoking cessation program | Arm Label: Smoking Cessation Program; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based smoking cessation program | Intervention Type: BEHAVIORAL; Name: Web-based smoking cessation program; Assigned to Arm(s): Smoking Cessation Program, Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)
Brief Summary: This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once nightly at bedtime for the treatment of levodopa induced dyskinesia (LID) in subjects with Parkinson's disease (PD). The novel pharmacokinetic profile of ADS-5102 is expected to achieve i) maximal concentrations in the early morning through mid-day, when LID can be troublesome, and ii) lower concentrations in the evening, potentially reducing the negative impact of amantadine on sleep. This pharmacokinetic profile could enable higher doses to be tolerated with a once-nightly ER formulation than can be tolerated with an immediate-release formulation. The once-nightly dosing regimen may also provide enhanced convenience and compliance.

In a previous clinical study, ADS-5102 met its primary endpoint; LID was significantly reduced as measured by the change in UDysRS score over 8 weeks vs. placebo.


Options:
A: Arm Label: ADS-5102; Type: EXPERIMENTAL; Interventions: Drug: ADS-5102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: ADS-5102; Assigned to Arm(s): ADS-5102 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CVT-301 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: CVT-301 Low Dose | Arm Label: CVT-301 High Dose; Type: EXPERIMENTAL; Interventions: Drug: CVT-301 High Dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CVT-301 Low Dose; Assigned to Arm(s): CVT-301 Low Dose | Intervention Type: DRUG; Name: CVT-301 High Dose; Assigned to Arm(s): CVT-301 High Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Early Multi-Ex-PD; Type: EXPERIMENTAL; Interventions: Behavioral: Balance & Strengthening Exercises | Arm Label: Late Multi-Ex-PD; Type: EXPERIMENTAL; Interventions: Behavioral: Balance & Strengthening Exercises | Intervention Type: BEHAVIORAL; Name: Balance & Strengthening Exercises; Assigned to Arm(s): Early Multi-Ex-PD, Late Multi-Ex-PD
D: Arm Label: Rotigotine; Type: EXPERIMENTAL; Interventions: Drug: Rotigotine | Intervention Type: DRUG; Name: Rotigotine; Assigned to Arm(s): Rotigotine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Brief Summary: maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in Cystic Fibrosis


Options:
A: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF
B: Arm Label: Creon N, then Creon®; Type: EXPERIMENTAL; Interventions: Drug: Creon® | Arm Label: Creon® , then Creon N; Type: EXPERIMENTAL; Interventions: Drug: Creon N | Intervention Type: DRUG; Name: Creon®; Assigned to Arm(s): Creon N, then Creon® | Intervention Type: DRUG; Name: Creon N; Assigned to Arm(s): Creon® , then Creon N
C: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pancrelipase Delayed Release | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pancrelipase Delayed Release; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Translating Telephonic Diabetes Self-management Support to Primary Care Practice: The NYC Care Calls Trial
Brief Summary: The goal of this study is to evaluate the implementation and effectiveness of an intervention to improve diabetes self-management, emotional distress and metabolic control among adults with type 2 diabetes receiving care in primary care practices throughout New York City. The program will be implemented by the New York City Department of Health, through their Primary Care Improvement Project.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Transplant navigator | Intervention Type: BEHAVIORAL; Name: Transplant navigator; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Control
B: Arm Label: Telephonic Diabetes Self-Management Support; Type: EXPERIMENTAL; Interventions: Behavioral: Telephonic Diabetes Self-Management Support | Arm Label: Educational Print Materials; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational Print Materials | Intervention Type: BEHAVIORAL; Name: Telephonic Diabetes Self-Management Support; Assigned to Arm(s): Telephonic Diabetes Self-Management Support | Intervention Type: OTHER; Name: Educational Print Materials; Assigned to Arm(s): Educational Print Materials
C: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention
D: Arm Label: Behavioral Activation Treatment for Depression; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for Depression Treatment | Arm Label: Supportive Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Counseling | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for Depression Treatment; Assigned to Arm(s): Behavioral Activation Treatment for Depression | Intervention Type: BEHAVIORAL; Name: Supportive Counseling; Assigned to Arm(s): Supportive Counseling

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healing and Empowering Alaskan Lives Towards Healthy-Hearts Study
Brief Summary: This study aims to identify effective and cost-effective interventions for tobacco use and other risk behaviors for cardiovascular disease among Alaska Native people in rural villages. In a randomized controlled trial, the study will compare interventions using telemedicine to promote the American Heart Association's identified ideal health behaviors (nonsmoking and physical activity) relative to ideal health factors (managing cholesterol and blood pressure).


Options:
A: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app
B: Arm Label: Tobacco/Physical Activity Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco/Physical Activity Intervention | Arm Label: Diet plus BP/CHOL Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet plus BP/CHOL Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco/Physical Activity Intervention; Assigned to Arm(s): Tobacco/Physical Activity Intervention | Intervention Type: BEHAVIORAL; Name: Diet plus BP/CHOL Intervention; Assigned to Arm(s): Diet plus BP/CHOL Intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Smoking Cessation Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone Quitline Smoking Cessation Program | Intervention Type: BEHAVIORAL; Name: Telemedicine Smoking Cessation Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Telephone Quitline Smoking Cessation Program; Assigned to Arm(s): 2
D: Arm Label: Information Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking Coach | Arm Label: QUIT-PRIMO; Type: EXPERIMENTAL; Interventions: Behavioral: Decide2Quit | Intervention Type: BEHAVIORAL; Name: Decide2Quit; Assigned to Arm(s): QUIT-PRIMO | Intervention Type: BEHAVIORAL; Name: Smoking Coach; Assigned to Arm(s): Information Prescription

Answer: B